Related Experiment Video
Updated: Oct 9, 2025
09:43
Author Spotlight: Unveiling the Polyfunctionality and Heterogeneity in Immune Responses
Published on: March 8, 2024
1.9K
Severe Immune Thrombocytopenia Post-COVID-19: A Case Report
Adrian Davoodian1, Chukwuemeka Umeh1, Elli Novatcheva1
1Internal Medicine, Hemet Global Medical Center, Hemet, USA.
Cureus
|December 22, 2021
Summary
Idiopathic thrombocytopenic purpura (ITP) can occur after viral infections like COVID-19. This case highlights ITP secondary to COVID-19, successfully treated with corticosteroids.
Area of Science:
- Hematology
- Infectious Diseases
- Immunology
Background:
- Immune thrombocytopenia (ITP), or idiopathic thrombocytopenic purpura, is a recognized complication following viral infections.
- The ongoing COVID-19 pandemic continues to reveal diverse clinical manifestations and sequelae.
- Thrombocytopenia is a significant concern, necessitating thorough investigation into its underlying causes.
Observation:
- A 48-year-old male presented with severe foot pain, incidentally found to have a critically low platelet count (7x10^3/mL).
- The patient had a recent history of hospitalization for COVID-19 approximately five weeks prior to presentation.
- Initial investigations ruled out other common causes of thrombocytopenia.
Findings:
- A diagnosis of idiopathic thrombocytopenic purpura (ITP) secondary to COVID-19 was presumed due to the temporal association and lack of alternative etiologies.
- The patient's platelet count significantly improved following treatment with corticosteroids.
Implications:
- This case underscores the potential for COVID-19 to trigger immune-mediated conditions like ITP.
- Early recognition and appropriate management, such as corticosteroid therapy, are crucial for favorable outcomes in post-COVID-19 ITP.
- Further research is warranted to elucidate the precise mechanisms linking SARS-CoV-2 infection to immune thrombocytopenia.
